Shamburg News · 8-K filed Oct 1, 2026, 8:01 AM EDT

Evommune Presents Phase 2a Proof-of-Concept Data for EVO301 in Atopic Dermatitis

EVMN · Evommune, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: medium

On October 1, 2026, Evommune, Inc. issued a press release furnished under Regulation FD presenting late-breaking Phase 2a proof-of-concept data for EVO301 in adults with moderate-to-severe atopic dermatitis at the EADV 2026 Congress. The company reported a 55% least-squares mean reduction in EASI from baseline at Week 12 versus 22% on placebo, and plans to initiate a subcutaneous Phase 2b dose-ranging trial in mid-2027. Treatment-related adverse events occurred in 10.4% of EVO301-treated patients compared with 13.6% on placebo.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001193125-26-409865.

Written from the filing by Shamburg Markets. Figures are as reported by the company.